Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza
Laiba Immad
Thu, February 19, 2026 at 11:33 AM GMT+9 2 min read
In this article:
NBIX
+0.49%
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds.
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) takes second position on our list of most promising stocks.
TheFly reported on February 12 that Needham lowered its price target on NBIX to $185 from $187 and maintained a Buy rating. The company is still hopeful about Crenessity’s growth in 2026 and anticipates robust double-digit growth for Ingrezza, which is in line with consensus forecasts of $2.72 billion. The firm also emphasized Neurocrine’s pipeline, which is backed by two active Phase 3 programs and could offer a new medication every two years.
Earlier on February 11, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported fourth-quarter revenue of $805.5 million, which exceeded the $789.3 million consensus estimate. The management emphasized that the 2025 results show the commercial portfolio’s robustness and the company’s ongoing progress toward diversification as a biopharmaceutical business. The business intends to advance a pipeline led by late-stage initiatives and drive steady growth from INGREZZA and CRENESSITY (crinecerfont) through 2026. Osavampator for major depressive disorder and direclidine for schizophrenia are important Phase 3 assets. NBIX’s growing commercial base and developing clinical pipeline, according to the leadership, put it in a position to create long-term value for stakeholders and increase its influence on patients across a range of neuropsychiatric diseases.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a neuroscience‑focused biopharmaceutical firm developing innovative psychiatric and neurological treatments. While not a classic psychedelic company, it still explores next‑generation mental health therapies with psychedelic‑like mechanisms targeting depression and schizophrenia through novel neuropsychiatric drug research.
While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
****READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts ****and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.
Disclosure: None.
Terms and Privacy Policy
Privacy Dashboard
More Info